Kevin joined the Board on 29 September 2014, when he assumed the role of Chief Executive Officer. He has over 20 years of experience in senior management roles in the chemical, technology and pharmaceutical sectors and brings significant marketing, strategy and business management expertise, along with a broad technical understanding, to Revolymer’s management team. Kevin joined Revolymer from Isogenica Ltd, a business providing drug discovery services to the pharmaceutical industry, where he served as CEO since 2009. Prior to that, he led the chemical technology company Oxonica as its CEO for eight years, during which time he completed its AIM listing in 2005 and secured numerous significant partnership deals and M&A transactions. He is currently serving as a non-executive director of the performance materials business Low and Bonar PLC and, between 2005 and 2014, was a non-executive director of the FTSE 250 specialty chemicals company, Elementis plc, where he helped to oversee a significant and successful strategic repositioning of the business. He was also a non-executive director of Cellectricon AB, a Swedish private biotechnology business from 2011 to 2014. Kevin began his career holding a number of increasingly senior roles at ICI, Albright & Wilson and Rhodia. He is a graduate of the University of Oxford, where he was also awarded a DPhil in Organic Chemistry.